Your browser doesn't support javascript.
loading
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
Rozeman, Elisa A; Versluis, Judith M; Sikorska, Karolina; Hoefsmit, Esmée P; Dimitriadis, Petros; Rao, Disha; Lacroix, Ruben; Grijpink-Ongering, Lindsay G; Lopez-Yurda, Marta; Heeres, Birthe C; van de Wiel, Bart A; Flohil, Claudie; Sari, Aysegul; Heijmink, Stijn W T P J; van den Broek, Daan; Broeks, Annegien; de Groot, Jan Willem B; Vollebergh, Marieke A; Wilgenhof, Sofie; van Thienen, Johannes V; Haanen, John B A G; Blank, Christian U.
Afiliação
  • Rozeman EA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Versluis JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Sikorska K; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Hoefsmit EP; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Dimitriadis P; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Rao D; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lacroix R; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Grijpink-Ongering LG; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lopez-Yurda M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Heeres BC; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van de Wiel BA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Flohil C; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Sari A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Heijmink SWTPJ; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Broeks A; Core Facility and Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Groot JWB; Isala Oncology Center, Isala, Zwolle, The Netherlands.
  • Vollebergh MA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wilgenhof S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Thienen JV; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands c.blank@nki.nl.
J Immunother Cancer ; 11(7)2023 07.
Article em En | MEDLINE | ID: mdl-37479483
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Melanoma Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Melanoma Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article